Core Insights - The American Journal of Transplantation position paper emphasizes the importance of decentralized organ health testing, particularly highlighting the role of absolute quantification of donor-derived cell-free DNA (dd-cfDNA) as a diagnostic marker, which aligns with iMDx's GraftAssure family of assays [1][2] Industry Context - The STAR working group, a collaboration between the American Society of Transplantation and the American Society for Histocompatibility and Immunogenetics, advocates for high-quality, standardized decentralized dd-cfDNA testing to support multicenter studies and improve patient management [2][3] - The publication indicates a significant demand for decentralized testing solutions in the transplant community, which is seen as a positive indicator for iMDx's business strategy [2][3] Company Strategy - iMDx aims to provide industry-leading molecular diagnostic test kits that decentralize access to organ health testing for kidney transplant patients, targeting a market exceeding $1 billion for transplant rejection testing [3][4] - The company is focused on developing a high-quality assay with transparent quality control to enhance access to dd-cfDNA testing, which is viewed as a promising biomarker for transplant rejection [3][4] Product Overview - iMDx's GraftAssure product line includes: - GraftAssureCore: A laboratory-developed test currently reimbursed by CMS and performed at iMDx's CLIA-certified lab [6] - GraftAssureIQ: A research-use-only kit for non-clinical applications [6] - GraftAssureDx: An in vitro diagnostic kit under development for clinical decision-making [6]

Core Insights - Insight Molecular Diagnostics Inc. has appointed Dr. Nick Ioannou as Vice President of Medical Affairs, bringing extensive experience in organ transplant, nephrology, cardiology, genetics, and oncology [1][5] Company Overview - Insight Molecular Diagnostics is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [6] Dr. Nick Ioannou's Background - Dr. Ioannou has over three decades of experience in clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs, with significant collaboration with key opinion leaders in various therapeutic areas [2] - His previous roles include senior positions at Guardant Health, Natera, LA Ort Institute, L-Nutra, and CSL Behring, among others [3] - He has nearly 10 years of experience as a medical director and partner in private clinics, enhancing his ability to connect with patients and healthcare professionals [4] Strategic Importance of Appointment - The CEO of iMDx, Josh Riggs, emphasized that Dr. Ioannou's expertise is crucial for the company as it prepares to launch its first commercial products in transplant rejection testing [5] - Dr. Ioannou expressed enthusiasm about joining iMDx, highlighting the need for improved transplant rejection testing paradigms [5]

Group 1 - Insight Molecular Diagnostics Inc. (iMDx) announced participation in investor conferences hosted by H.C. Wainwright and Lake Street Capital Markets [1] - The H.C. Wainwright 27th Annual Global Investment Conference will take place on September 8-9, 2025, featuring a company presentation on September 8 at 5:00 pm ET [1] - The Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9) is scheduled for September 11, 2025, with a format of one-on-one meetings [1] Group 2 - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [2] - The company holds several trademarks, including GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ [2]

Core Insights - Oncocyte Corp. will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025, with CEO Josh Riggs and CFO Andrea James attending [1][3] - The focus of the discussion will be on Oncocyte's innovative diagnostic technologies and the progress towards commercializing a regulated organ transplant rejection monitoring test kit [2][4] Company Overview - Oncocyte is a diagnostics technology company that provides tests aimed at enhancing clarity and confidence for physicians and patients [4] - Key products include: - VitaGraft™: A clinical blood-based solid organ transplantation monitoring test - GraftAssure™: A research use only (RUO) blood-based solid organ transplantation monitoring test - DetermaIO™: A gene expression test for predicting response to immunotherapies - DetermaCNI™: A blood-based monitoring tool for assessing therapeutic efficacy in cancer patients [4][5]